Blue background of abstract painting

The Virta treatment reverses type 2 diabetes and other chronic metabolic diseases, safely and sustainably, without the risks, costs, or side effects of medications or surgery. Our mission is to reverse type 2 diabetes in 100 million people by 2025.

Read Virta's full story

Looking for assets?

Download our press kit for the latest logos, product screenshots and company photos.

Media Inquiries

For inquiries, feel free to contact us at any time:





Raised through Series C


States where Virta is available

About Virta




Raised through Series C


States where Virta is available

Diabetes Trends (US)


People living with type 2 diabetes


People living with prediabetes


Economic burden of diabetes

Virta's Clinical Trial


Diabetes reversal rate* at 1 year¹


Patients who reduced or eliminated insulin at 1 year¹


Estimated savings per patient for the first two years²

As Featured In

Forbes logoFortuneThe New York Times logoNewsweek logoTechCrunch logoLogo: Business Insider

Press Releases

Brand assets

Virta logo in the foreground; Virta clinicians, Dr. Jeff Stanley and Dr. Caroline Roberts, in the background

Press Kit

Logos, screenshots, photography, and more.
Download our Press Kit
Photo of the Virta office, showing a seating area in the lobby

Video B-Roll

Virta people, places, and patients for media use and beyond. Higher resolution video available upon request.
Download our Video B-Roll

Citations and Footnotes

  1. Hallberg SJ, McKenzie AL, Williams P, et al. Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at One Year: An Open Label, Non-Randomized, Controlled Study. Diabetes Ther. 2018. DOI: 10.1007/s13300-018-0373-9. Reversal rate refers to % of patients with HbA1c less than 6.5% who are taking no diabetes-specific medications.
  2. Note: does not include consideration of Virta fees. Source: Virta internal analysis - Economic Impact Model built using Virta clinical results and published estimates of medical & pharmacy costs by A1c level and BMI from Li et. al., The Economic Burden of Obesity by Glycemic Stage in the United States; PharmacoEconomics (2015) 33:735–748.